9 research outputs found
Sensor-controlled scalp cooling to prevent chemotherapy-induced alopecia in women treated for either breast or female genital tract cancer: A German experience using the Paxman system.
No full textPO73 OUTPATIENT CATUMAXOMAB THERAPY IN METASTATIC BREAST CANCER PATIENTS SUFFERING FROM MALIGNANT EFFUSIONS DUE TO PERITONEAL OR PLEURAL CARCINOMATOSIS: A SINGLE INSTITUTION EXPERIENCE
No full textPrimary prophylaxis of febrile neutropenia using long-acting granulocyte colony-stimulating factors in female patients receiving dose-dense biweekly chemotherapy in the clinical routine.
No full textDirect effects on bone metabolism induced by perioperative anthracycline- and/or taxane-based chemotherapy depend on the menopausal status of patients with primary breast cancer.
No full textIncidence of abnormal HER2 values in the serum of breast cancer patients: influence of disease stage and HER2 status.
No full textThe effect of biochar with biogas digestate or mineral fertilizer on fertility, aggregation and organic carbon content of a sandy soil: Results of a temperate field experiment
No full textWhole-exome sequencing identifies tetratricopeptide repeat domain 7A ( TTC7A ) mutations for combined immunodeficiency with intestinal atresias
No full textAdvanced spectroscopic, microscopic, and tomographic characterization techniques to study biogeochemical interfaces in soil
No full textThe management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry
Get PDFBackground: Venous thromboembolism (VTE) is a major health problem, with over one million events every year in Europe. However, there is a paucity of data on the current management in real life, including factors influencing treatment pathways, patient satisfaction, quality of life (QoL), and utilization of health care resources and the corresponding costs. The PREFER in VTE registry has been designed to address this and to understand medical care and needs as well as potential gaps for improvement. Methods/design: The PREFER in VTE registry was a prospective, observational, multicenter study conducted in seven European countries including Austria, France Germany, Italy, Spain, Switzerland, and the UK to assess the characteristics and the management of patients with VTE, the use of health care resources, and to provide data to estimate the costs for 12 months treatment following a first-time and/or recurrent VTE diagnosed in hospitals or specialized or primary care centers. In addition, existing anticoagulant treatment patterns, patient pathways, clinical outcomes, treatment satisfaction, and health related QoL were documented. The centers were chosen to reflect the care environment in which patients with VTE are managed in each of the participating countries. Patients were eligible to be enrolled into the registry if they were at least 18 years old, had a symptomatic, objectively confirmed first time or recurrent acute VTE defined as either distal or proximal deep vein thrombosis, pulmonary embolism or both. After the baseline visit at the time of the acute VTE event, further follow-up documentations occurred at 1, 3, 6 and 12 months. Follow-up data was collected by either routinely scheduled visits or by telephone calls. Results: Overall, 381 centers participated, which enrolled 3,545 patients during an observational period of 1 year. Conclusion: The PREFER in VTE registry will provide valuable insights into the characteristics of patients with VTE and their acute and mid-term management, as well as into drug utilization and the use of health care resources in acute first-time and/or recurrent VTE across Europe in clinical practice. Trial registration: Registered in DRKS register, ID number: DRKS0000479
